Intense Pulsed Light (IPL) is an insufficient technology for the treatment of the Meibomian Glands Dysfunction (MGD). Following years of research, Espansione Group has developed an innovative device for the treatment of MGD, and other related pathologies, that is radically different from existing treatments.
EYE-LIGHT LINE RESOLVES THE IPL LIMITATIONS
The IPL can be only applied to the lower eyelids. This implies that the Meibomian Glands located in the upper eyelid could not be treated.
Thanks to our combined therapy and our innovative design, the treatment of both, upper and lower meibomian glands is now possible. In addition, Eye-light allows us to treat other frequent related pathologies, such as chalazion, stye, blepharitis, post-blepharoplasty, demodex and dry eye caused by refractive and cataract surgery.
Being more effective and safer than current intense pulsed light treatments, its combination with innovative low-level light therapy (LLLT) technology enhances cellular processes through mitochondrial cytochrome c oxidase modulation
— Stonecipher K, Abell TG, Chotiner B, Chotiner E, Potvin R. (2019). Combined low level light therapy and intense pulsed light therapy for the treatment of meibomian gland dysfunction. Clinical Ophthalmology, 13, 993–999